RNS Number:8995K
Bioquell PLC
09 May 2003


TO: COMPANIES ANNOUNCEMENT OFFICE

FOR IMMEDIATE RELEASE


                                                                      9 May 2003



                                  BIOQUELL PLC
                                  CONTRACT WIN
            For RBDS (Room Bio-Decontamination Service) in Singapore


BIOQUELL, the UK developer of a unique and patent-protected range of
bio-decontamination technology, today announces that it has been awarded a
contract by Parkway Group Healthcare Ltd, Singapore's leading private hospital
group, to bio-decontaminate parts of their hospitals. The text of the Parkway
press release is set out below.


                                     * * *

Parkway Group Healthcare Is First to Adopt State-of-the-Art Bio-Decontamination
                     Technology in Bid to Remain SARS Free


Parkway Group Healthcare, Singapore's leading private healthcare group, has
appointed UK-based bio-decontamination experts, BIOQUELL to deploy its unique
infection control technology at its two larger hospitals, Gleneagles and Mount
Elizabeth. Bio-decontamination processes will be carried out first at Mount
Elizabeth Hospital followed by Gleneagles Hospital.


BIOQUELL's unique Room Bio-Deactivation Service - RBDS - was launched recently
in the UK and it is a fast, highly effective and safe method to sterilize
hospital rooms and other medical facilities. RBDS comprises modular ("infinitely
scalable"), low temperature, residue-free equipment which uses hydrogen peroxide
vapour to bio-deactivate bacteria, viruses and moulds.


RBDS has been successfully tested against a range of hospital acquired infection
- otherwise known as nosocomial infection - such as MRSA and VRE as well as
against anthrax (Bacillus anthracis) spores. BIOQUELL's technology has also been
selected for priority verification by the US Environmental Protection Agency,
acting under the auspices of the US Homeland Security Agency, for its Safe
Building Program


Commenting on the appointment of BIOQUELL, Parkway Group Healthcare Managing
Director Dr Lim Cheok Peng, said, "Parkway is determined to keep its hospitals
at the cutting edge of healthcare innovation and the deployment of BIOQUELL's
RBDS room-sterilisation technology demonstrates Parkway's commitment to
providing patients with the best possible healthcare". Dr Lim further stressed
that "Parkway's hospitals are SARS-free; however, putting in place this
technology ensures that a proactive, preventative and robust approach is taken
to infection control in all our hospitals".


RBDS was developed to provide room / building sterilization for (i) the
healthcare; (ii) bio-defence; and (iii) pharmaceutical / biotechnology sectors
and the technology is also used to sterilise rooms and equipment in the
pharmaceutical and biotechnology sectors. The micro-biological test BIOQUELL
uses to check the efficacy of its RBDS process is the same test used to validate
hospital steam sterilisers. Upon completion of the bio-deactivation process, the
hydrogen peroxide vapour is catalytically converted into water and oxygen thus
ensuring that the process is environmentally friendly.


Nick Adams, Chief Executive of BIOQUELL, said, "We are delighted to help Parkway
with the deployment of our unique, state-of-the-art RBDS service. Following
BIOQUELL's RBDS process, the Parkway hospitals will, quite literally, have the
most micro-biologically clean rooms and wards in the world."

1

                                     * * *

About Parkway Group Healthcare

Parkway Group Healthcare is Asia's largest healthcare organisation with an
extensive network of hospitals and integrated healthcare facilities in the
region. It owns East Shore, Gleneagles and Mount Elizabeth Hospitals in
Singapore and seven hospitals in the region. Parkway Group Healthcare is a
wholly-owned subsidiary of Singapore-listed Parkway Holdings Limited.
        
                                    
                                - Ends - 



For more information please contact:

Parkway Group Healthcare, Corporate Communications

April Lee    DID: 65-6720 0090, e-mail: aml_lee@gleneagles.com.sg

Chris Cheung DID: 65-6720 0093, e-mail: cyl_cheung@gleneagles.com.sg


B.M. Bodeker          BIOQUELL PLC              01264 835 900

Katharine Sharkey     Redleaf Communications    020 7955 1410

                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
CNTSSDFSUSDSESI